Dyne Therapeutics (DYN) Net Equity Issued and Repurchased (2020 - 2025)

Dyne Therapeutics (DYN) has reported Net Equity Issued and Repurchased for 4 consecutive years, with $377.7 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $377.7 million; the TTM figure through Jun 2026 stood at $377.7 million (up 168.53% YoY), while the FY2025 annual figure was $140.7 million, up 43.71% from the prior year.
• Net Equity Issued and Repurchased climbed to $377.7 million in Q4 2025 per DYN's latest filing, from $140.7 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $377.7 million in Q4 2025 and bottomed at -$1000.0 in Q4 2023.
• Historically, Net Equity Issued and Repurchased has averaged $95.5 million across 3 years, with a median of $28.2 million in 2023.
• On a YoY basis, Net Equity Issued and Repurchased climbed as much as 160.81% in 2024 and fell as far as 0.45% in 2024.
• Dyne Therapeutics' Net Equity Issued and Repurchased stood at -$1000.0 in 2023, then jumped by 2425100.0% to $24.2 million in 2024, then soared by 1457.53% to $377.7 million in 2025.
• Business Quant data shows DYN's Net Equity Issued and Repurchased at $377.7 million in Q4 2025, $140.7 million in Q1 2025, and $24.2 million in Q2 2024.